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Background: Malaria is still a public health problem in Malaysia with chloroquine (CQ) being the first-line drug in
the treatment policy of uncomplicated malaria. There is a scarcity in information about the magnitude of
Plasmodium falciparum CQ resistance. This study aims to investigate the presence of single point mutations in the
P. falciparum chloroquine-resistance transporter gene (pfcrt) at codons 76, 271, 326, 356 and 371 and in
P. falciparum multi-drug resistance-1 gene (pfmdr1) at codons 86 and 1246, as molecular markers of CQ resistance.
Methods: A total of 75 P. falciparum blood samples were collected from different districts of Pahang state, Malaysia.
Single nucleotide polymorphisms in pfcrt gene (codons 76, 271, 326, 356 and 371) and pfmdr1 gene (codons 86
and 1246) were analysed by using mutation-specific nested PCR and restriction fragment length polymorphism
(PCR-RFLP) methods.
Results: Mutations of pfcrt K76T and pfcrt R371I were the most prevalent among pfcrt gene mutations reported by
this study; 52% and 77%, respectively. Other codons of the pfcrt gene and the positions 86 and 1246 of the pfmdr1
gene were found mostly of wild type. Significant associations of pfcrt K76T, pfcrt N326S and pfcrt I356T mutations
with parasitaemia were also reported.
Conclusion: The high existence of mutant pfcrt T76 may indicate the low susceptibility of P. falciparum isolates to
CQ in Peninsular Malaysia. The findings of this study establish baseline data on the molecular markers of
P. falciparum CQ resistance, which may help in the surveillance of drug resistance in Peninsular Malaysia.Background
Anti-malarial drug resistance is a major challenge to the
control of falciparum malaria, the leading cause of mor-
bidity and mortality especially in Africa and southern
Asia [1]. The first P. falciparum chloroquine resistance
was reported in the late 1950s in Southeast Asia along
the Thai-Cambodian border [2,3]. Further spread of CQ
resistance was shown later to include neighboring coun-
tries in Asia, South America and Africa [4-8]. Moreover,
P. falciparum has been also reported resistant to other
anti-malarial drugs including sulphadoxine/pyrimeth-
amine drug combination, mefloquine, atovaquone and
artemisinin [9-12].* Correspondence: halmekhlafi@yahoo.com
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reproduction in any medium, provided the orThree methods have been commonly used for moni-
toring anti-malarial drug efficacy and to screen for drug
resistance; in vivo test, in vitro test and, more recently,
the detection of molecular markers of anti-malarial drug
resistance [13]. CQ resistance has been associated with
point mutations in two genes; P. falciparum chloroquine
resistance transporter (pfcrt) and multidrug resistance 1
(pfmdr1). It is well documented that the mutation at
codon 76 of the pfcrt gene (pfcrt K76T), resulting in the
substitution of threonine for lysine at position 76, is a
key marker of P. falciparum CQ resistance [14]. How-
ever, the role of pfmdr1 point mutations on CQ resist-
ance P. falciparum isolates remains a matter of debate.
In Malaysia, malaria is still a public health problem
especially in the interior parts of the Peninsula and
the states of Sabah and Sarawak (East Malaysia), with
P. falciparum and Plasmodium vivax being the pre-
dominant species. A previous in vivo study followed by al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ducted in Sarawak and showed that CQ resistance oc-
curred widely and therefore, CQ was replaced by
sulphadoxine/pyrimethamine (SDX/PYR), and later by ar-
temisinin combination therapy, as the drug of choice for
treating uncomplicated falciparum malaria infections in
East Malaysia [15]. In West Malaysia, CQ is still used as
the first-line drug in the treatment policy of uncompli-
cated malaria caused by P. falciparum, although a previ-
ous in vivo study reported a CQ resistance rate of 63.6%
among uncomplicated falciparum malaria patients [16].
Data on the molecular markers of CQ resistance in
Peninsular Malaysia is not available. Therefore, this study
was carried out to detect the molecular markers of anti-
malarial drug resistance based on P. falciparum chloro-
quine resistance transporter (pfcrt) and P. falciparum
multidrug resistance 1 (pfmdr1) genes.
Methods
Study area
This study was carried out in Pahang state which is the
largest state in Malaysia after Sabah and Sarawak (East
Malaysia). The state is divided into 11 administrative
districts and is located in the eastern North Kuala Lum-
pur with an area of 36,137 km2 and a total population of
1,443,365. The climate is equatorial with an average
temperature of 21-32°C and an annual rainfall of between
2,000- 2,500 mm. Relative humidity in such areas is in the
range of 80%. The economy is mostly agricultural; palm oil,
natural rubber and timber are the major primary commo-
dities. Malaria is endemic in Pahang, with P. falciparum
and P. vivax accounting for the majority of reported cases.
Sampling and malaria microscopy
A total of 822 blood samples were collected from the
different districts of Pahang (728 survey-based blood
samples and 94 archived positive falciparum malaria
slides) (Figure 1). The survey was conducted between
May 2010 and May 2011 while the archived slides are
for cases reported between 2007 and 2009. During the
survey, finger prick blood samples were collected from
participants in 20 villages of different districts of Pahang,
and thick and thin blood films were prepared. Filter
paper blood spots were also collected from each participant
on 3MM WhatmanW filter paper (Whatman International
Ltd., Maidstone, England), and kept in clean, dry and well-
sealed separate plastic bags for molecular analysis. Demo-
graphic data of the participants were collected by a stand-
ard semi structural questionnaire throughout face-to-face
interview during the sampling survey. For archived slides,
data was collected from the patients’ records.
Thick and thin blood films were stained with 10% diluted
Giemsa and examined microscopically for the presence of
malaria. About 200 fields under 1,000x magnification wereexamined from the thick film before the slide was consid-
ered negative. Parasitaemia was calculated by counting the
asexual stages of the parasite against 300 white blood cells
(WBC) and multiplied by 7500 as an assumed average total
WBC count for the individuals [17]. Parasitaemia was cate-
gorized as low (< 1,000 parasites/μl of blood), moderate
(1,000 – 9,999 parasites/μl of blood) and high (≥ 10,000
parasites/μl of blood). Archived malaria positive slides were
also re-examined and parasitaemia were recorded.
Molecular identification of Plasmodium species
Genomic DNA was extracted from filter papers blood
spots and from archived blood smears. Briefly, a disc of
the filter paper blood spot (approximately 6 mm diam-
eter) was punched out using a methanol-flamed puncher
and placed in 1.5 ml centrifuge tubes using clean and
flamed forceps. Archived slides were first cleaned with
chloroform to remove oil and 50 ml of TE buffer was
transferred onto the smear. The smear was completely
wiped off the slide using small Whatman filter paper
disc (cut by flamed-sterile puncher) and transferred into
1.5 ml microcentrifuge tubes. Genomic DNA was
extracted using Qiagen blood and tissue kit (QIAGEN,
DNeasyW Blood & Tissue Kit, Cat. no. 69506, Germany)
according to the manufacurer’s instruction. DNA extract
was finally eluted using 50 μL Qiagen AE elution buffer
and kept at −20°C until used. Plasmodium species were
identified using genus-specific and species-specific primers
in nested PCR based on small subunit ribosomal RNA
(18 s rRNA) gene [18]. PCR reaction and cycling conditions
were conducted as mentioned previously [19].
Molecular detection of pfcrt and pfmdr1 mutations
The detection of mutations of different positions of pfcrt
and pfmdr1 genes was performed using mutation-
specific nested PCR and restriction fragment length
polymorphism (PCR-RFLP) according to the protocols
described previously [14,20].
Primers for pfcrt K76T primary amplification were
TCRP1 and TCRP2 while the secondary PCR was con-
ducted by using the forward primer CRTP3 and the re-
verse primers TCRP4 m and TCRP4 w for mutant and
wild types, respectively. Pfcrt Q271E alleles were ampli-
fied using primer set of CRT2a and CRT2b in the pri-
mary PCR and CRT271a and CRT271b in the secondary
PCR. Amplification of N326S, I356T and R371I pfcrt muta-
tions was carried out using the same primer set (CRT-3a
and CRT-3b) in the first reaction, while secondary reactions
were done using CRT326a and CRT326b, CRT356a and
CRT356b, and CRT371a and CRT371b, respectively. A
20 μl reaction volume containing 8 μl of the secondary
PCR amplicons and 1 unit of specific endonuclease diges-
tion enzyme was incubated overnight at 37°C. The restric-
tion enzymes XMN1, MSe1, AlwN1 and AflII were used
Figure 1 A geographic map shows Peninsular Malaysia and Pahang’s districts.
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while the mutant pfcrt allele T76 remained uncut.
For the detection of pfmdr1 gene mutations (N86Y
and D1246Y), primers sets (MDR-A and MDR-B) and(1246-A and 1246-B) were used for the primary amplifi-
cation of pfmdr1 86 and pfmdr1 1246, respectively while
the secondary PCR was conducted using primers sets
(MDR-D1 and MDR-D2) and (1246-D1 and 1246-D2)
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1246 codons, respectively. Then, the Pfmdr1 N86Y and
D1246Y amplicons were digested using Af1III and Bg1II
restricted enzymes, respectively. The primers and PCR
reagents were from iNtRON (iNtRON Biotechnology,
Inc. Seoul, Korea). All PCR products were resolved by
electrophoresis in a 2% agarose gel stained with SYBR
safe and visualized by UV-transilluminator.
Genomic DNA of HB3, 3D7 and Dd2 strains of
P. falciparum provided by Malaria Research and Reference
Reagents Resources Centre (MR4, ATCCW, Manassas VA,
USA) were used as positive controls for wild and mutant
types, respectively.
Ethical consideration
The protocol of this study (Reference Number: 788.73)
has been approved by the Medical Ethics Committee of
the University of Malaya Medical Centre, Kuala Lumpur,
Malaysia. The study was also registered with the Na-
tional Medical Research Registry, Malaysia (Research ID:
5681). Before the commencement of sampling, the
objectives of the study were explained to the people in
their village setting and consents were obtained from
those who have agreed to participate in the study.
Statistical analysis
Data was analysed using the SPSS statistical package ver-
sion 13. Statistical associations between point mutations
and parasitaemia were assessed using the Chi-square test
with Yates' continuity correction. When the number of
expected observations in one or more cells in a 2×2 con-
tingency table is less than 5, Fisher’s Exact test was used. A
p value≤0.05 was considered statistically significant.
Results
Of the 822 collected samples, 728 were collected by
sampling surveys in 20 villages of different districts ofFigure 2 Distribution of pfcrt and pfmdr1 alleles in Plasmodium falcipPahang, and 94 were archived malaria positive slides
from different health centres, hospitals and malaria con-
trol units in the same study area. Plasmodium falciparum
parasites were detected in 75 of the total collected samples
(64 from archived slides and 11 from surveys). Based on
these 75 slides, the mean age of participants was
27.8± 4.1 years and 66% were males. The majority of parti-
cipants were Malay (64.2%) followed by Aborigines (23.9),
Indians (6.5%) and Chinese (2.7%). Moreover, 2 slides
(2.7%) were from foreign workers who were residing
in Malaysia for the past three years.
Plasmodium falciparum parasite density ranged from 50
asexual parasites/μl of blood to 17,100 with a parasitaemia
geometric mean of 4,065 asexual parasites/μl. Moderate-
to-high parasitaemic individuals (parasite count≥ 1,000
parasites/μl of blood) were more frequent 58.7% while
individuals with low parasitemia represented 41.3%.
All falciparum positive slides were examined for single
nucleotide polymorphisms (SNP) at five positions of
pfcrt gene (K76T, Q271E, N326S, I356T and R371I) and
two positions of pfmdr1 genes (N86Y and D1246Y), and
the results are shown in Figure 2. The detection rate was
100% for all positions of pfcrt and pfmdr1 markers ex-
cept for 76 and 271 position of pfcrt (98.7%); one sample
was negative for each of them. Of pfcrt point mutations,
pfcrt K76T and pfcrt R371I had higher mutant alleles
than other positions (52% and 77%, respectively). Other
positions showed predominance for the wild type with
rates of 93%, 88% and 76% for the pfcrt Q271, pfcrt
N326 and pfcrt I356, respectively. Moreover, polymorph-
ism analysis of pfmdr1 revealed a high predominance of
wild type for both markers; 95% and 96% for pfmdr1
N86 and pfmdr1 D1246, respectively.
The association of mutations at different codons of
pfcrt and pfmdr1 with the parasitaemia, age of partici-
pant, gender, race and year of infection was examined
(Table 1). Of the five positions of mutation at pfcrt gene,arum isolates from Pahang, Malaysia.
Table 1 Association between parasitaemia and different point mutations of pfcrt and pfmdr1 genes
Locus Alleles Parasitaemia χ2
significanceLow (< 1,000/μl) Moderate to high (≥1,000/μl)
Pfcrt 76 Mutant 8 31 <0.001
Wild 23 13
Pfcrt 271 Mutant 0 4 0.138*
Wild 31 40
Pfcrt 326 Mutant 0 9 0.009*
Wild 31 35
Pfcrt 356 Mutant 1 17 <0.001*
Wild 30 27
Pfcrt 371 Mutant 22 36 0.409
Wild 9 8
Pfmdr1-86 Mutant 0 4 0.138*
Wild 31 40
Pfmdr1-1246 Mutant 0 3 0.263*
Wild 31 41
* Fisher’s Exact test.
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associations with moderate-to- high parasitaemia as
compared to low parasitaemia (p < 0.01). On the other
hand, the association of pfcrt mutations with age, race,
gender of participants and year of infection was not sig-
nificant (p > 0.05). Similarly, the association of pfmdr1
gene mutations at positions 86 and 1246 with the tested
variables was not significant.
Discussion
This is the first study in Peninsular Malaysia on the de-
tection of molecular markers of pfcrt and pfmdr1 for
chloroquine and other anti-malarial drugs resistance.
The high prevalence rate (52%) of pfcrt K76T point mu-
tation reported by the present study reflects low suscep-
tibility of P. falciparum to the CQ. This is in agreement
with previous studies in Malaysia and neighbouring
countries including Thailand, Indonesia and Philippine
[15,16,21-23]. In Sarawak (East Malaysia), Cox-Singh
et al. reported a strong association of pfcrt K76T with
in vitro CQ resistance; pfcrt K76T was found higher at a
fixation level (100%) in all isolates resistant to CQ [15].
Similar detection rates of mutant pfcrt T76 with a sig-
nificant association with in vitro CQ resistance had also
been reported in Thailand and Philippine [21,23].
Previous studies in other countries have showed such
association between pfcrt K76T mutation and in vivo re-
sistance of P. falciparum to CQ. In Mali, the presence of
pfcrt K76T mutation was reported in all infections oc-
curred within two weeks of administration of chloro-
quine while it was absent in all isolates that respondedwell to CQ [14,24]. Similar findings were reported in
Uganda, Sudan and Yemen [19,25,26]. In the same vein,
a previous study aimed at comparing two areas with dif-
ferent susceptibility levels to CQ found that the preva-
lence of wild type of pfcrt K76 was higher in areas with
lower CQ resistance, while the mutant type was higher
in areas with higher CQ resistance [27].
Except for pfcrt 371, the findings showed that other
examined codons of the pfcrt gene (271, 326 and 356) were
found mostly of wild type represented 93%, 88% and 76%,
respectively. Moreover, pfcrt R371I mutation was detected
in 77% of the isolates. Previous reports had suggested a cor-
relation between CQ resistance and the accumulation of
point mutations in the pfcrt gene [28,29]. However, the role
of these mutations in conferring CQ resistance is unclear
and suggested to have a complementary effect in maintain-
ing the functional property of transporter protein [14,30].
Thus, further studies to explain the role of these mutations
including pfcrt R371I are required.
Regarding pfmdr1, the present study showed a pre-
dominance of wild type of both pfmdr1 N86 and pfmdr1
D1246 (95% and 96%, respectively). The role of pfmdr1
gene mutations in anti-malarial drugs resistance is still
controversial. Previous in vivo studies reported the ab-
sence of mutations at codons pfmdr1 86 and 1246 in the
CQ resistant infections [31-33]. Similarly, a previous study
in south-eastern Iran reported a strong association between
pfcrt K76T, but not pfmdr1 N86Y mutation and in vivo CQ
resistance [34]. In contrast, a recent study from Madagascar
reported an association between pfmdr1 Y86 mutant alleles
and CQ clinical resistance with no such association with
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pfmdr1 mutations in P. falciparum can confer resistance to
high levels of chloroquine, and that these pfmdr1 mutations
has an important role in the resistance of P. falciparum to
mefloquine and quinine [36].
The high prevalence of wild alleles of pfmdr1 N86 and
pfmdr1 D1246 could be considered as an indicator for
low susceptibility of P. falciparum isolates to meflo-
quine, amodiaquine and quinine [21,37-40]. On the
other hand, previous studies have found increased sensi-
tivity to the anti-malarials mefloquine and artemisinin in
P. falciparum isolates with mutations in the pfmdr1 gene
[41,42]. However, a previous in vivo study in Thailand
found that treatment failure with mefloquine is signifi-
cantly associated with increased pfmdr1 copy number
but not with the single point mutations [43].
The present study found a significant association between
moderate-to-high parasitaemia and pfcrt point mutations at
codons 76, 326 and 356. This is in agreement with previous
studies in Tanzania, Sudan, Nigeria and Yemen [19,44,45].
However, studies from Sudan and Gabon showed no sig-
nificant association between the pfcrt point mutations and
severity of malaria [46,47]. Moreover, a recent study in the
Yemen found higher frequency of pfcrt K76T mutation in
P. falciparum isolates from patients aged>10 years as com-
pared to younger individuals [19]. On the other hand, a
previous study among Nigerian children aged≤12 years
with acute uncomplicated P. falciparum malaria showed
that the association between the presence of both mutant
pfcrt T76 and pfmdr1 Y86 alleles with in vivo anti-malarial
drug resistance was age dependent [38]. However, the
present study found no significant association between gene
point mutations and age of patients. Most of the positive
samples in this study were from adult patients aged 22–
40 years, and this limited range of age may constraint
examining such association.Conclusions
The high prevalence of mutation at codon 76 of the pfcrt
gene (pfcrt K76T) is a key indicator of P. falciparum CQ re-
sistance spread in Peninsular Malaysia. A further study to
examine the implemented malaria drug policy using PCR-
corrected anti-malarial drug efficacy trail in large sample
set nationally is recommended. Continuous molecular sur-
veillance using pfcrt and pfmdr1 genes as molecular mar-
kers of chloroquine resistance are highly recommended in
both East and West Malaysia, for monitoring the efficacy of
chloroquine in Peninsular Malaysia and for the re-
emergence of wild-type of P. falciparum in East Malaysia
(Sarawak and Sabah).Competing interests
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